anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Novel compounds of the Formula I wherein R1 represents a hydrogen or halogen atom or a hydroxy or acyloxy group and R2 represents a hydrogen atom, or R1 and R2 together represent a keto group; R3 represents an unsubstituted or substituted amino group and R4 and R5 each represent a halogen atom or a trifluoromethyl, alkyl, alkoxy, alkylthio, acyl, sulphamyl or alkylsulphamyl group and the broken lines indicate that the substituent attached thereby is optional; and ketals and acid addition salts thereof, are prepared by reacting a compound of the Formula II wherein R6 represents a hydroxy group, R7 represents a hydrogen atom and R8 represents a halogen atom or R6 and R7 together represent an oxo group or R6 and R8 together represent an oxygen bridge, or a ketal thereof, with ammonia or an appropriate amine and, if desired, converting the product by acylation of the 10-hydroxy group if present or replacement of the hydroxy group by a halogen atom; acylation at any unsubstituted or monosubstituted amino group; or ketalation and, if desired, converting a resulting free base into an acid addition salt.  Compounds of the Formula I where R1 represents a hydrogen atom are prepared by reductive dehalogenation of the corresponding compound of the Formula I wherein R1 represents a halogen atom.  Trans-compounds of the Formula I are converted into cis-compounds of said formula by methods known per se. <FORM:1068451/C2/1> <FORM:1068451/C2/2> Dibenzocycloheptenones of the Formula II where R6 represents a hydroxy group and R8 represents a halogen atom may be prepared by treating the corresponding dibenzocycloheptenones with an agent which yields a hypohalous acid in the presence of water or by treating the corresponding compound where R6 and R8 together represent an oxygen bridge with a magnesium halide.  Dibenzocycloheptenones of the Formula II where R6 and R7 together represent an oxo group and R8 represents a halogen atom may be prepared by oxidation of the corresponding compounds of the Formula II wherein R6 represents a hydroxy group.  10,11 - Epoxy - 10,11 - dihydro - 5H - dibenzo-[a,d] - cyclohepten - 5 - one may be prepared by the action of hydrogen peroxide on 5H-dibenzo-[a,d]-cyclohepten-5-one.  d,l - cis - 2 - Phenyl - 3a,12b - dihydro - 8H - dibenzo - [3,4,6,7] - cyclohept - [1,2-d] - oxazol - 8 - one hydrochloride is prepared by reacting d,l - trans - 10 - hydroxy - 11 - benzamido - 10,11-dihydro - 5H - dibenzo - [a,d] - cyclohepten -5-one with thionyl chloride.  Therapeutic compositions with antidepressant properties, in the form of tablets, dragees, capsules, solutions, emulsions, suspensions, salves and suppositories, for oral, parenteral and topical application, comprise compounds of the Formula I and ketals and acid addition salts thereof in admixture with a compatible pharmaceutical carrier.
Patients will be prescreened for inclusion criteria one week before the start of screening at Visit 0 (Prescreening Visit). Patients must be on stable doses of azathioprine/mercaptopurine. Patients will be given a diary to record their CD symptoms for the seven days prior to Visit 1. At Visit 1 (Screening Visit 1), patients will have their CDAI score assessed based upon their diary information. Patients with CDAI ≤ 220 will then have both calprotectin and hsCRP testing done. Patients with calprotectin \> or = 250µg/g and/or hsCRP \> or = 5mg/L will be notified and told to schedule Visit 2 within three weeks. At Visit 2 (Screening Visit 2), patients will undergo a colonoscopy. A Crohn's Disease Endoscopic Index of Severity (CDEIS) will be used to determine the endoscopic activity. Patients with significant endoscopic lesions will be notified and asked to enroll in the study.

Patients will be randomized into the study at Visit 3 (Randomization Visit, same day of Visit 2 in results available). Due to the cost and invasiveness of the colonoscopy, the Screening Visit 2 colonoscopy will serve as the baseline for the study, should the patient be enrolled. Drug will also be dispensed at this visit. Eligible patients will be randomized in a 1:1 ratio to receive either adalimumab or placebo during the treatment period, along with continuing their current immunosuppressive maintenance treatment at a stable dose. Treatment in both arms will be induction at 160/80mg and maintenance on 40 mg every other week.

Patients will return for follow up visits every 12 weeks until the final follow-up visit at 48 weeks (Visit 7), where another colonoscopy will be performed. Patients who terminate early from the study for any reason will be asked to return for a follow-up visit, where Visit 7 procedures will be performed.

Before week 48, if a patient has an increase of more than 50% in either calprotectin and/or hsCRP over baseline and above the thresholds at any regular visit, a follow-up visit will be performed two weeks later. If the 50% increase is still observed another colonoscopy will be performed, within two weeks of the follow-up visit. If patients still have significant endoscopic lesions, study product will be intensified to 40 mg weekly. This will include patients on placebo in order to preserve the double-blind aspect of the study.
1. A cosmetic product for removing keratotic skin plugs comprising: (i) a flexible non-occlusive substrate sheet; and (ii) a composition containing a poly(methyl vinyl ether/maleic anhydride) copolymer in an amount from 50 to 100% by weight of the composition deposited onto the substrate sheet, the composition being dry non-tacky to the touch after deposition and upon being wetted for use the composition turns tacky and mobile. 2. The product according to claim 1 wherein the substrate is a breathable fabric. 3. The product according to claims 1 or 2 wherein the fabric is selected from the group consisting of rayon, polyester, polypropylene and mixtures thereof. 4. The product according to any preceding claim wherein the deposited polymer and substrate are present in a weight ratio ranging from 0.1:1 to 1,000:1. 5. The product according to any preceding claim wherein the polymer is water-soluble. 6. The product according to any preceding claim wherein mobility of the composition is characterized by a yield point ranging from 1 to 400 Pascals. 7. A cosmetic method for removing keratotic plugs from skin pores comprising: (a) wetting an area of skin to be treated with a wetting agent comprising a fluid; (b) applying a plug removing product onto the area, the product comprising: (i) a flexible non-occlusive substrate sheet; and (ii) a composition containing a poly(methyl vinyl ether/maleic anhydride) copolymer in an amount from 50 to 100% by weight of the composition deposited onto the substrate sheet, the composition being dry non-tacky to the touch after deposition and upon being wetted for use the composition turns tacky and mobile; (c) allowing the fluid to tackify the composition and then to evaporate from, the area covered by the product thereby causing the composition to dry in contact with the skin; and (d) peeling away the product from the skin thereby removing keratotic plugs now adhesively attached to the composition. 8. The method according to claim 7 wherein the fluid is selected from the group consisting of water, alcohol and mixtures thereof. 9. A cosmetic method for removing keratotic plugs from skin pores through use of a cosmetic product, the product comprising: (i) a flexible non-occlusive substrate sheet; and  (ii) a composition containing a poly(methyl vinyl ether/maleic anhydride) copolymer in an amount from 50 to 100% by weight of the composition <DP=3deposited onto the substrate sheet, the composition being dry non-tacky to the touch after deposition and upon being wetted for use the composition turns tacky and mobile; the method comprising: (a) placing a wetting agent comprising a fluid onto a surface of the cosmetic product whereon the composition is deposited thereby turning the composition into a tacky and mobile material; (b) applying the wetted cosmetic product onto an area of skin to be treated; (c) allowing fluid to evaporate from the area covered by the product; and (d) peeling away the product from the skin thereby removing keratotic plugs now adhesively attached to the composition. 10. The method according to claim 9 wherein the fluid is selected from the group consisting of water, alcohol and mixtures thereof.
Inspect vials visually for particulate matter and discoloration prior to administration. If particulate matter or discoloration is observed, the vial should not be used. With a syringe, extract the appropriate volume of cidofovir injection from the vial and transfer the dose to an infusion bag containing 100 mL 0.9% (normal) saline solution. Infuse the entire volume intravenously into the patient at a constant rate over a one hr period. Use of a standard infusion pump for administration is recommended.

It is recommended that cidofovir injection infusion admixtures be administered within 24 hr of preparation and that refrigerator or freezer storage not be used to extend this 24 hr limit.

If admixtures are not intended for immediate use, they may be stored under refrigeration (2°C to 8°C) for no more than 24 hr. Refrigerated admixtures should be allowed to equilibrate to room temperature prior to use.

The chemical stability of cidofovir injection admixtures was demonstrated in polyvinyl chloride composition and ethylene/propylene copolymer composition commercial infusion bags, and in glass bottles. No data are available to support the addition of other drugs or supplements to the cidofovir admixture for concurrent administration.

Cidofovir injection is supplied in single-dose vials. Partially used vials should be discarded (see Handling and Disposal).

Compatibility with Ringer's solution, Lactated Ringer's solution or bacteriostatic infusion fluids has not been evaluated.
In this trial, olaparib will be delivered alone for 14 days with the hypothesis that priming of the apoptotic machinery will be required prior to introduction of the senolytic agent (navitoclax). To date navitoclax and olaparib have not been combined in the clinic. The Phase I study will therefore be conducted to define the recommended Phase II dose (RP2D). A plan for a future Phase II study will depend on the results obtained during this Phase I trial. Based on the potential for overlapping toxicity (particularly hematologic toxicity) an interrupted dosing schedule will be used for the navitoclax. Based on preclinical studies it is believed that intermittent delivery of the senolytic agent is in line with the proposed mechanism of action. Subsequently the dose of navitoclax will be escalated with a fixed dose of olaparib in 28-day cycles.
The present invention relates to a biologically active preparation containing a hazelnut albumin extract, eleutherosides and a physiological solution in the following amounts: from 5 to 15 wt.% of hazelnut albumin extract, from 10 to 45 wt.% of eleutherosides, the balance consisting of physiological solution. This preparation contains as eleutherosides lignans selected from the group comprising A, B, C, D, E, F and P lignans. This invention also relates to a complex of preparations containing the above-mentioned biologically active preparation as well as average therapeutic doses of an isonicotinic acid hydraside, an alkylating compound and a food acid. This complex uses as isonicotinic acid hydraside an ethyoamide, a saluside, a tubaside or a metaside. The alkylating compound is a thiophosphamide while the food acid may consist of acetic, citric or malic acid. This complex is used in effective quantities for restoring the immune system. The albumin preparation can be administered by injection on a daily basis according to a ratio of between 0.001 and 0.05 g per 1 kg of the body mass, while the other preparations in the complex are administered perorally due to their average therapeutic doses.
The present invention provides a vaccine adjuvant consisting of a combination of a surfactant i.e. dimethyldioctadecylammonium-bromide/chloride (DDA) and a lipid extract from The present invention provides a vaccine adjuvant consisting of a combination of a surfactant i.e. dimethyldeoctadecylammonium-bromide/chloride (DDA) and a lipid extract from <The present invention provides a vaccine adjuvant consisting of a combination of a surfactant i.e.  dimethyldeoctadecylammonium-bromide/chloride (DDA) and a lipid extract from Mycobacterium bovis. The present invention provides a vaccine adjuvant consisting of a combination of a surfactant i.e. dimethyldeoctadecylammonium-bromide/chloride (DDA) and a lipid extract from Mycobacterium bovis <The present invention provides a vaccine adjuvant consisting of a combination of a surfactant i.e. dimethyldeoctadecylammonium-bromide/chloride (DDA) and a lipid extract from Mycobacterium bovis BCG The present invention provides a vaccine adjuvant consisting of a combination of a surfactant i.e.  dimethyldeoctadecylammonium-bromide/chloride (DDA) and a lipid extract from Mycobacterium bovis BCG<The present invention provides a vaccin adjuvant consisting of a combination of a surfactant i.e. dimethyldeoctadecylammonium-bromide/chloride (DDA) and a lipid extract from Mycobacterium bovis BCG. The present invention provides a vaccine adjuvant consisting of a combination of a surfactant i.e. dimethyldeoctadecylammonium-bromide/chloride (DDA) and a lipid extract from <i>Mycobacterium bovis BCG<i>. <The present invention provides a vaccine adjuvant consisting of a combination of a surfactant i.e.  dimethyldeoctadecylammonium-bromide/chloride (DDA) and a lipid extract from <i>Mycobacterium bovis BCG<i>. The total lipid extract contains both apolar 1ipids, polar lipids, and lipids of intermediate polarity of which the apolar lipids were found to induce the most powerful immune responses. The total lipids may be extracted with chloroform/methanol and re-dissolved in water before the addition of surfactant. This preparation may be used to induce prominent cell-mediated immune responses in a mammal in order to combat pathogens, or as a treatment for cancer.
This provider- administered brief- counseling intervention program will increase Women Veteran?s self- efficacy in addressing violence in their current or past relationships. The variable length (up to six- session) modular-based intervention aims at providing resources for WVs in the relevant domains of: 1) safety planning, 2) education on health effects of IPV, 3) improving coping and self- care and red flags, 4) enhancing social support, 5) making difficult decisions, and 5) connecting with resources.
Latent disease may be activated or there may be an exacerbation of intercurrent infections due to pathogens, including those caused by Candida, Mycobacterium, Ameba, Toxoplasma, Pneumocystis, Cryptococcus, Nocardia, etc.

Corticosteroids may activate latent amebiasis. Therefore, it is recommended that latent or active amebiasis be ruled out before initiating corticosteroid therapy in any patient who has spent time in the tropics or in any patient with unexplained diarrhea. 

Similarly, corticosteroids should be used with great care in patients with known or suspected Strongyloides (threadworm) infestation. In such patients, corticosteroid-induced immunosuppression may lead to Strongyloides hyperinfection and dissemination with widespread larval migration, often accompanied by severe enterocolitis and potentially fatal gram-negative septicemia.

Corticosteroids should not be used in cerebral malaria.
The present disclosure is drawn to nail enamel compositions including cannabis sativa seed oil, and specifically to nail enamel compositions including a plasticizer, a solvent, a film forming polymer, and cannabis sativa seed oil. The plasticizer may be, e.g., a citric acid and/or benzoic acid derivative, and may be present in a total amount of between 1.0% and 10.0% by weight. The solvent may be, e.g., ethyl acetate, propyl acetate, butyl acetate, ethyl lactate, isopropanol, and/or propylene carbonate, and may be present in a total amount of at least 10%. The film forming polymer may include, e.g., a cellulose derivative and/or may include two or more polymers. The film forming polymer may be present in a total amount of between 5.0% and 70.0% by weight. The composition may include a colorant, such as a pigment, and the pigment may be present in an amount of at least 0.5% by weight.
PROBLEM TO BE SOLVED: To obtain the subject medicine capable of suppressing synthesis of a specific heat shock protein and suppressing collagen synthesis in organs and enabling treatment of diseases such as hepatocirrhosis or interstitial lung disease by including shikonin as an active ingredient. SOLUTION: This medicine contains shikonin as an active ingredient. Shikonin is included in a crude medicine such as shikon. Shikon extract can be obtained by extracting shikon with water (e.g. cold water, warm water or hot water) or an organic solvent. Thereby, since heat shock protein having 47K dalton molecular weight in the cell is specifically suppressed and biosynthesis of collagen is suppressed, production of extracellular matrix is suppressed and the medicine can be used for prevention and treatment of hepatocirrhosis or interstitial lung disease.
The expected symptoms with overdosage are those of excessive beta-adrenergic stimulation and/or occurrence or exaggeration of any of the symptoms listed under ADVERSE REACTIONS, eg, seizures, angina, hypertension or hypotension, tachycardia with rates up to 200 beats per minute, arrhythmias, nervousness, headache, tremor, dry mouth, palpitation, nausea, dizziness, fatigue, malaise, and insomnia.

Hypokalemia may also occur. As with all sympathomimetic medications, cardiac arrest and even death may be associated with abuse of PROAIR RESPICLICK.

Treatment consists of discontinuation of PROAIR RESPICLICK together with appropriate symptomatic therapy. The judicious use of a cardioselective beta-receptor blocker may be considered, bearing in mind that such medication can produce bronchospasm. There is insufficient evidence to determine if dialysis is beneficial for overdosage of PROAIR RESPICLICK.
A package for delivery of a physiologically acceptable lubricant comprises a solid lubricant precursor that on exposure to moisture forms the physiologically acceptable lubricant, housed in a capsule capable of disintegration on exposure to moisture at a temperature in the range 35°C - 45°C and encapsulated by an outer protective membrane inhibiting exposure of the capsule to moisture. In some embodiments, the inner capsule may be in the form of a sachet or bag. Preferably the capsule is made from poly vinyl alcohol (PVA). In an embodiment, the capsule disintegrates within 15 seconds of exposure to water at 25℃. The lubricant precursor preferably comprises powdered sucrose, poly(ethylene oxide) and fumed silica. In some embodiments the outer membrane is compostable. For use the capsules are removed from the outer membrane and placed in the required position, preferably in the vagina of an animal.
A measurement system comprising a measurement device and a computer. The measurement device is configured to measure a force, pressure, or load applied by the musculoskeletal system. The measurement device comprises an enclosure and a structure configured to fit within an opening in the enclosure. The enclosure is hermetically sealed housing electronic circuitry and at least one sensor. The structure is configured to couple to the musculoskeletal system. At least three sensors underlie and couple to the structure to measure a force, pressure, or load applied to a surface of the structure. The structure includes at least three anti-cantilevering structures. At least one of the three anti-cantilevering structures is configured to couple to the enclosure to limit canting of the structure when the musculoskeletal system couples to the surface of the structure outside a predetermined area.
This invention relates to superior bioadhesive compositions having time extended adhesive properties comprising a non-toxic carrier and a polymer having between about 45 and about 70 weight % of units having the structure (A). between about 50 and about 30 weight % of units having the structure (B). and/or (C). and 2 to 7 weight % of an amine salt containing a lactam functionality derived from A and/or B, wherein R is hydrogen, alkoxy, phenyl, carboxyl or -N lactam having from 3 to 6 carbon atoms; R1? is C1? to C6? alkylene and R2? is C2? to C4? alkylene; said copolymer having a number average molecular weight of about 40,000 to about 500,000 and a relatively small particle size. The invention also relates to the method of synthesizing and using the above composition.
Aging is associated with an increased incidence and severity of various cardiovascular disorders. Previously, our laboratory has demonstrated an age-related shift in the substrates used by the heart for metabolism from primarily fatty acids to primarily glucose. Furthermore, other institutions have demonstrated that a similar shift can be induced, in animal models, with specific nitric oxide synthase inhibitors, such as L-NAME (N-Nitro-L-Arginine Methyl Ester). Our hypothesis is that a reduction in nitric oxide (NO) synthesis is responsible for the age-related shift in heart function. Accordingly, we aim to demonstrate, in young patients, an acute, transient shift in substrate use from fatty acids to glucose with L-NMMA (citrate) in association with depressed heart function. Also, we aim to demonstrate in the elderly an acute, transient shift in substrate use from glucose to fatty acids with L-arginine, in association with improved cardiac function. These results will demonstrate a portion of the mechanism for the age-related shift in substrate utilization.

Each participant will undergo a screening visit which will include a Glucose Tolerance Test, an echocardiogram in conjunction with a treadmill stress test to exclude cardiac disease, and baseline blood work. Then each patient will have 3 PET study days, each lasting about 5-6 hours. During this time, the patient will have two IVs (one in each arm). They will have 4 injections of different radioactive isotopes (015 Water, C11 Acetate, C11 Glucose, and C11 Palmitate). After each injection, about 8-10 blood samples will be drawn over the course of about ½ to 1 hour of time. In between each injection, there will be about an hour break for the patient to rest and move around. During one of the breaks, the patient will have another echocardiogram. On the day 2 and 3 PET, the patient will have a 30-60 minute infusion of L-NAME. Then the PET study will commence. After the study is over the participant will have a 10-minute infusion of L-arginine to reverse the effects of L-NAME.
Lung transplantation (LTx) is a well-known treatment for end-stage lung disease. This study aimed to report the incidence of cancer after LTx and long-term outcome among lung transplant recipients with a pretransplant diagnosis of cancer. Patients who underwent LTx between 1990-2016 were included in the study. Detection of cancer was obtained by cross-checking the study population with the Swedish Cancer Registry and the Cause-of-Death registry. A total of 614 patients were followed for a median of 5.1 years. In all, 159 malignancies were diagnosed. The excess risk of cancer or standardized incidence ratio (SIR) following LTx was 5.6-fold compared to the general Swedish population. The most common malignancies were non-melanoma skin cancer (NMSC) (SIR 76.5 (95%CI 61.7-94.8); non-Hodgkin lymphoma (SIR 23.5, 95%CI 14.8-37.2); and lung cancer (SIR 8.89, 95%CI 5.67-13.9). There was no significant difference in overall survival between those with and without a history of cancer before LTx (p = 0.56). In total, 159 malignancies were identified after LTx, which was a 5.6-fold higher relative to the general population. A history of previous cancer yields similar survival in selected recipients, compared to those without cancer prior to LTx.